Sign in
Taking people in FrancePhase 3

Imaging scan to study lung artery changes in pulmonary arterial hypertension

Tests 68Ga-FAPI PET/CT imaging for lung artery changes in pulmonary arterial hypertension.

Key facts

Who runs it
Centre Hospitalier Regional Et Universitaire De Brest
Where
Brest, FranceSee the site
Registry title
SOFAPI
Status
Recruiting
Phase
Phase 3
People taking part
15 people, planned
Started
29 Oct 2026
Expected to end
15 Mar 2027
Type of study
Interventional
Record updated
15 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with pulmonary arterial hypertension (PAH) who are about to start sotatercept, to test a PET/CT scan with 68Ga-FAPI.

Age
18 years or older
Sex
All sexes
Disease stage
Symptomatic PAH, WHO functional class II or III. PAH types: idiopathic, heritable, drug/toxin-induced, linked to connective tissue disease, or linked to simple congenital shunts at least 1 year after repair. A right heart catheterization within 12 months must show PVR of at least 4 Wood units and PCWP or LVEDP of 15 mmHg or less.
Earlier treatment
Already on double or triple background PAH therapy, and about to be started on Sotatercept.

Main reasons for not taking part

  • PH of WHO Groups 2, 3, 4 or 5
  • HIV-associated PAH, PAH with portal hypertension, schistosomiasis-associated PAH, pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis
  • Pregnant or breastfeeding women
  • eGFR below 30 mL/min/1.73 m2, or ALT, AST or total bilirubin above 3 × ULN
  • Known allergy to sotatercept (ACE-011), its excipients, or luspatercept

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • 18 years old or more
  • Documented diagnostic right heart catheterization (RHC) within 12 months of screening documenting a minimum PVR of ≥ 4 Wood units and pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) of ≤ 15 mmHg, with the diagnosis of WHO PAH Group 1 in any of the following subtypes: o Idiopathic PAH o Heritable PAH o Drug/toxine-induced PAH o PAH associated with connective tissue disease o PAH associated with simple, congenital systemic-to- pulmonary shunts at least 1year following repair
  • Patients under bi or tri-background-therapy
  • Symptomatic PAH classified WHO FC II or III
  • Patients will be started on Sotatercept
  • Ability to adhere to study visit schedule and understand and comply with all the protocol requirement
  • Ability to understand and provide written informed consent

Who cannot take part

  • Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, schistosomiasis associated PAH, pulmonary veno occlusive disease and pulmonary capillary hemangiomatosis
  • A known allergy has been identified with sotatercept (ACE-011), its excipients, or luspatercept
  • Hemoglobin at screening above gender-specific ULN, per local laboratory test
  • Any of the following clinical laboratory values at the Screening Visit: - eGFR < 30 mL/min/1.73 m2 (as defined by MDRD equation) - Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin levels > 3 × ULN
  • Diagnosis of PH WHO Groups 2, 3, 4, or 5
  • Pregnant or breastfeeding women

Where in France

  • Centre Hospitalier Régional et Universitaire de BrestBrest, FranceTaking people

About the trial

What the trial wants to find out

Our first objective is to assess whether [68Ga]Ga-FAPI PET/CT imaging can non-invasively assess pulmonary artery remodeling in PAH patients.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
68Ga-FAPI PET/CT imaging to assess pulmonary artery and right ventricle remodeling SoFAPI study
Plain-language title
Imaging scan to study lung artery changes in pulmonary arterial hypertensionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
15 September 2026